TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16200777
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of rhTPO at 1.0 microg/kg for 7 - 14 days
Study: 26291137
Drug: FF/VI 200/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 200/25 mcg
Study: 7838417
Drug: beta‐IFN therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐IFN therapy at a dose of 300,000 UI/die i.m. for 7 days, continuing the same dose on alternate days for 2 weeks
Study: 3283097
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg single dose
Study: 23906646
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) administered to the parent
Study: 19664250
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization (EPI)
Study: 19664250
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose infant formulations of IPTi
Study: 19664250
Drug: Newer drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drugs used in IPTi
Study: 17045409
Drug: Citalopram IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram IV infusion (20 mg over 120 min)
Study: 1577936
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release intrauterine insemination (treatment A)
Study: 1577936
Drug: Bolus intrauterine
Normalized name: UREA 13 g INTRAUTERINE TABLET [INTRAUTERINE BOLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intrauterine insemination (treatment B)
Study: 30997650
Drug: Optimal Sampling
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Sampling Strategy (OSS) using time points of 2, 4, and 8 hours post-dose for first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, pyrazinamide)
Study: 26891645
Drug: Pilates sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates sessions in addition to conventional treatment with occlusal splint
Study: 26891645
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with occlusal splint
Study: 22437411
Drug: Higher hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher hemoglobin (13-15 g/dl)
Study: 22437411
Drug: Lower hemoglobin
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower hemoglobin (9-11 g/dl)
Study: 18271233
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) warming therapy combined with oral administration of Pyridostigmine (90 ‐ 240 mg each day) and Prednisone (30 ‐ 60 mg each day)
Study: 18271233
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Pyridostigmine (240‐480 mg each day) and Prednisone (60‐100 mg each day)
Study: 16279900
Drug: PEG IFN
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG IFN alpha‐2b 1.5 microg/kg per wk plus RBV 800 mg per day (Regimen A)
Study: 16279900
Drug: PEG IFN
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG IFN alpha‐2b 1.0 microg/kg per wk plus RBV 1,000‐1,200 mg per day (Regimen B)
Study: 16279900
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy nonresponders
Study: 16279900
Drug: IFN monotherapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN monotherapy nonresponders
Study: 16279900
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy relapsers
Study: 16279900
Drug: HCV ribonucleic
Normalized name: ribonucleic acid sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV ribonucleic acid levels <100,000 copies/mL
Study: 11872551
Drug: Homoeopathic immunotherapy
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic immunotherapy
Study: 10195529
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of bupivacaine 0.25%
Study: 10195529
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of bupivacaine 0.5%
Study: 10195529
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of saline
Study: 9626172
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g TID for 6 months)
Study: 6126441
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg diacetolol
Study: 6126441
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg diacetolol
Study: 6126441
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg diacetolol
Study: 30233159
Drug: Resveratrol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (500 mg/day) with meloxicam (Mlx)
Study: 26818756
Drug: Muscle vibration
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle vibration treatment at 200 Hz
Study: 26818756
Drug: Muscle vibration
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle vibration treatment at 100 Hz
Study: 24818764
Drug: Low-dosage EPA-E
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage EPA-E (1800 mg/d)
Study: 24818764
Drug: High-dosage EPA-E
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage EPA-E (2700 mg/d)
Study: 22639399
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise program (1 hour twice a week)
Study: 18613959
Drug: 1-year group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year group behavioral program based on Self-Determination Theory (SDT) with 30 sessions of 2 hours each, delivered weekly or bi-weekly.
Study: 11818200
Drug: CEF14 (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF14 (chemotherapy every 14 days)
Study: 11818200
Drug: CEF21 (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF21 (chemotherapy every 21 days)
Study: 9880419
Drug: Collagen-gentamicin implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-gentamicin implant plus metronidazole 20 to 40 mg/kg/day IV for 7 days
Study: 9880419
Drug: Open wounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open wounds treated with local cleansing, metronidazole 20 to 40 mg/kg/day IV and gentamicin 5 mg/kg/day IV for 7 days
Study: 2024227
Drug: Ampicillin, gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, gentamicin and clindamycin (standard therapy)
Study: 28934785
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants
Study: 17507306
Drug: Enfuvirtide plus
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide plus one of the new ritonavir‐boosted protease inhibitors (tipranavir or darunavir) and an optimised background treatment regimen
Study: 10068730
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen PAC (pantoprazole 40 mg bid, clarithromycin 500 mg tid, amoxicillin 1 g bid)
Study: 2178870
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam daily
Study: 2178870
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac twice daily
Study: 88710
Drug: Hydromorphone (narcotic)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (narcotic) delivered in a demand analgesia (DA) system, dosage varied in response to patient-triggered apparatus.
Study: 27868359
Drug: Linagliptin add-on
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin add-on group (linagliptin 5 mg/day)
Study: 27868359
Drug: Metformin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin group (1,500 mg/day)
Study: 27868359
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (metformin 750 mg/day)
Study: 21312345
Drug: Pain-avoidance treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-avoidance treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Study: 21312345
Drug: Pain-persistence treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-persistence treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Study: 21312345
Drug: Pain-avoidance treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-avoidance treatment
Study: 21312345
Drug: Pain-persistence treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-persistence treatment
Study: 11484963
Drug: Vinorelbine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine at 25 mg/m2 weekly for at least eight weeks
Study: 7920274
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of one gram of Ambroxol in 500 ml of 0.9% saline daily for 5 days
Study: 7920274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received infusions of 500 ml 0.9% saline at the same intervals
Study: 25413366
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (AngII) infusion
Study: 19352186
Drug: Endoflex endotracheal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoflex endotracheal tube for oral intubation
Study: 19352186
Drug: Conventional endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional endotracheal tube with stylet for oral intubation
Study: 9405961
Drug: tianeptine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tianeptine (37.5 mg/day)
Study: 9405961
Drug: imipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine (150 mg/day)
Study: 9405961
Drug: tianeptine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: tianeptine (75 mg/day)
Study: 24469436
Drug: Oesophageal cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oesophageal cooling with ice water (5 mL injected prior to RF energy delivery)
Study: 22279570
Drug: Ang-2 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ang-2 levels in patients recently started on treatment
Study: 19684105
Drug: Standard doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
Study: 19013285
Drug: Strawberry supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry supplementation (454 g/d, 112 kcal)
Study: 19013285
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran bread (control, 65 g/d, 112 kcal, approximately 2 g beta-glucan)
Study: 9862876
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy for chronic hepatitis C (24 weeks duration)
Study: 9862876
Drug: Sustained viral
Normalized name: Sustain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained viral response to interferon therapy (n = 41)
Study: 9862876
Drug: Sustained biochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained biochemical responses to interferon therapy
Study: 8571994
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle exercises for 3 months (completed treatment)
Study: 1677698
Drug: Infusion-related bacteraemias
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion-related bacteraemias
Study: 21908754
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) treatment
Study: 17966977
Drug: Pomegranate ellagitannin-enriched
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 710 mg or 1420 mg per day
Study: 17966977
Drug: Pomegranate ellagitannin-enriched
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 1000 mg per day
Study: 14981375
Drug: Metronidazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (two 2-g doses, 48 hours apart)
Study: 12411539
Drug: Lactate clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate clamp (LC) procedure with exogenous lactate infusion clamped at approximately 4 mM during exercise at 55% V(O2,peak)
Study: 9820381
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (OAC)
Study: 9820381
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (AC)
Study: 7644398
Drug: Antituberculosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculosis treatment regimen including pyrazinamide, isoniazid, and rifampicin
Study: 806396
Drug: 2% solution
Normalized name: Lidomar 2% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% solution of sodium cromoglycate
Study: 30343388
Drug: rs11600655 CC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs11600655 CC, rs640908 CT, and rs66475048 GA genotypes
Study: 18469662
Drug: 0.01% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% lidocaine solution (10 mL of 1% lidocaine in 1 L saline)
Study: 11323346
Drug: Rapacuronium (RAP)
Normalized name: rapacuronium
DrugBank: Rapacuronium (DB04834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapacuronium (RAP) 1.5 mg/kg
Study: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium (VEC) 0.1 mg/kg
Study: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after RAP
Study: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after VEC
Study: 11323346
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after SUC
Study: 9182212
Drug: Abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab with low-dose heparin (initial bolus of 70 U per kilogram)
Study: 9182212
Drug: Abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab with standard-dose heparin (initial bolus of 100 U per kilogram)
Study: 9182212
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standard-dose heparin (initial bolus of 100 U per kilogram)
Study: 7894540
Drug: Zolpidem (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (therapeutic doses)
Study: 31603281
Drug: Soya lecithin
Normalized name: Soya Lecithin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya lecithin (1.5 g per day) in a custom-made biscuit
Study: 25673440
Drug: Kuntai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai capsule (4 capsules tid, po for 12 weeks)
Study: 25673440
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg qd, po for 12 weeks)
Study: 25673440
Drug: Blank Control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank Control (no drug addition)
Study: 20888993
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (chemotherapy started within 28 days of increased CA125 measurement)
Study: 20888993
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (chemotherapy commenced at clinical or symptomatic relapse)
Study: 18172907
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75 mg)
Study: 18172907
Drug: Venlafaxine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine IR (75 mg)
Study: 10939428
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with PEM regimen: cisplatin 60 mg/m2, etoposide 40 mg/m2, mitomycin-C 7 mg/m2
Study: 8755686
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg, once daily
Study: 1584996
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of mifepristone (RU 486)
Study: 3937189
Drug: Isoniazid and
Normalized name: Isoniazid and rifampin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid and Rifampicin without a third drug
Study: 29704965
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy Skills Training Group (DBT‐ST)
Study: 20728709
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 2% lidocaine with 1:50,000 epinephrine
Study: 20728709
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of 2% lidocaine with 1:50,000 epinephrine
Study: 18182617
Drug: Sequential docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF)
Study: 18182617
Drug: Concurrent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)
Study: 18182617
Drug: Control arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arms (sequential control: four cycles of doxorubicin at 75 mg/m2, followed by three cycles of CMF; concurrent control: four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF)
Study: 18182617
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment (both sequential and concurrent)
Study: 2331957
Drug: Cisapride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 10 mg four times a day
Study: 2331957
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg four times a day
Study: 25016597
Drug: Low FODMAP
Normalized name: ProNourish Low FODMAP Enteral Suspension (French Vanilla)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low FODMAP diet (3.05 g/day)
Study: 25016597
Drug: Typical Australian
Normalized name: Australian pine pollen extract
DrugBank: Casuarina equisetifolia pollen (DB10485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical Australian diet (23.7 g/day)
Study: 17925871
Drug: SP+AS+PQ (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP+AS+PQ (0.75 mg/kg primaquine)
Study: 10849921
Drug: Active feedback
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active feedback via practice visits from the pharmaceutical prescribing adviser
Study: 8973990
Drug: Metformin HCL
Normalized name: metformin HCl
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin HCL 1,700 mg (single dose)
Study: 8973990
Drug: Metformin HCL
Normalized name: metformin HCl
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin HCL 850 mg (multiple doses, 3 times daily for 19 doses)
Study: 8973990
Drug: Metformin HCL
Normalized name: metformin HCl
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin HCL (single and multiple doses) in healthy subjects
Study: 6085386
Drug: 5‐mg nitrendipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg nitrendipine tablet
Study: 6085386
Drug: 10‐mg nitrendipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg nitrendipine tablet
Study: 6085386
Drug: 20‐mg nitrendipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg nitrendipine tablet
Study: 6085386
Drug: Liquid suspension
Normalized name: Inhalation Suspension
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid suspension of nitrendipine
Study: 6085386
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses (5‐mg, 10‐mg, 20‐mg)
Study: 30046610
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at ST36-ST37, 20 minutes twice a day for five days
Study: 30046610
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies including fluid resuscitation, anti‐infection, vasoactive agents, mechanical ventilation, supply of enteral nutrition, and glutamine
Study: 27479098
Drug: Complicated Grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated Grief Treatment (CGT) with a supportive person
Study: 27479098
Drug: Complicated Grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated Grief Treatment (CGT) without a supportive person